If microbial ecosystem therapy can change your life, what's the problem?

被引:8
|
作者
Ettinger, Grace [1 ,2 ]
Burton, Jeremy P. [1 ,3 ]
Reid, Gregor [1 ,2 ,3 ]
机构
[1] Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada
[2] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada
[3] Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada
关键词
fecal; microbial; probiotics; regulatory; stool; substitute; transplantation; CLOSTRIDIUM-DIFFICILE INFECTION; FECAL MICROBIOTA; INTESTINAL MICROBIOTA; LACTOBACILLUS-CASEI; TRANSPLANTATION; PREVENTION; YOGURT; ECZEMA; AGE;
D O I
10.1002/bies.201300015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The increased incidence of morbidity and mortality due to Clostridium difficile infection, had led to the emergence of fecal microbial transplantation (FMT) as a highly successful treatment. From this, a 32 strain stool substitute has been derived, and successfully tested in a pilot human study. These approaches could revolutionize not only medical care of infectious diseases, but potentially many other conditions linked to the human microbiome. But a second revolution may be needed in order for regulatory agencies, society and medical practitioners to accept and utilize these interventions, monitor their long term effects, have a degree of control over their use, or at a minimum provide guidelines for donors and recipients.
引用
收藏
页码:508 / 512
页数:5
相关论文
共 50 条